Life Sciences

  • April 30, 2026

    Kratom Seller Sanctioned For Deleting Blog During Suit

    A California federal judge has sanctioned Ashlynn Marketing Group Inc. in a suit alleging it hid kratom's dangerous and addictive effects, finding that it deliberately deleted a blog containing statements about kratom after the suit was filed.

  • April 29, 2026

    J&J, Neutrogena Say FDA Signed Off On Benzene Products

    Johnson & Johnson Consumer Inc. and Kenvue Inc. are calling for a permanent end to a multistate consumer lawsuit claiming their Clean & Clear and Neutrogena acne treatments degrade into the cancer-causing chemical benzene, arguing in New Jersey federal court that federal regulators have already determined that the key ingredient is safe.

  • April 29, 2026

    Feds Say Lack Of Injury Dooms Gold Card Program Challenge

    The Trump administration said a suit challenging the gold card visa program's legality must be thrown out because the immigrants and academic professionals union that filed it can't show the program hurts their chances at getting visas.

  • April 29, 2026

    High Court Seeks Path To Limited Ruling On 'Skinny Labels'

    The U.S. Supreme Court on Wednesday appeared reluctant to craft new standards for deciding whether makers of generic drugs that use so-called skinny labels have encouraged others to infringe patents, with several justices saying existing law is sufficient to make a decision.

  • April 29, 2026

    Deloitte Can't Duck Bulk Of Vax Software Theft Suit

    Deloitte must face an inventor's trade secrets misappropriation claims accusing the consulting giant of ripping off her firm's proprietary vaccination management system and securing a multimillion-dollar government contract to track the rollout of COVID-19 vaccines.

  • April 29, 2026

    Squires Snubs 10 IPRs While 4 Pass Muster In Latest Order

    U.S. Patent and Trademark Office Director John Squires rejected 10 petitions for America Invents Act patent reviews and granted four challenges in an order marking the roughly half-year mark since he took over the duty of making institution decisions.

  • April 29, 2026

    CEO Stole From His Company To Buy Mansion, SEC Says

    The former CEO of a California-based pharmaceutical company agreed Wednesday to pay the U.S. Securities and Exchange Commission $30,000 to end a lawsuit accusing him of misappropriating $3.2 million in company funds partly to buy a Beverly Hills mansion.

  • April 29, 2026

    3 Federal Circuit Clashes To Watch In May

    The Federal Circuit's May argument slate includes appeals of invalidity decisions and sanctions tied to VLSI Technology's multibillion-dollar chip patent dispute with Intel, as well as Amazon's challenge to a cloud storage patent verdict against it for over half a billion dollars.

  • April 29, 2026

    Novo Nordisk Rejects Claim It Influences GLP-1 Market

    Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an antitrust suit it is facing.

  • April 29, 2026

    PBMs Say Michigan AG Price-Fixing Suit Is Unsound

    Pharmacy benefit managers Express Scripts, Evernorth Health and Prime Therapeutics have bolstered their effort to escape a federal price-fixing suit brought against them by Michigan's attorney general by arguing the statutes cited in the complaint do not apply to them.

  • April 29, 2026

    Teva Acquires Tourette's Drugmaker For Up To $900M

    Biopharmaceutical company Teva Pharmaceuticals, advised by Faegre Drinker Biddle & Reath LLP, on Wednesday announced plans to acquire Bradley Arant Boult Cummings LLP-advised Emalex Biosciences for up to $900 million.

  • April 29, 2026

    Bausch Balks At Suspected Tweak In Price-Fixing Deals

    A stipulation between state attorneys general and private plaintiffs suing generic-drug makers for alleged price-fixing seems to reflect a change in the states' earlier deal to release claims against Bausch entities, the companies said in asking a Connecticut federal judge to maintain the status quo.

  • April 29, 2026

    AbbVie Seeks Early Win Over HHS In Botox Drug Price Suit

    When the federal government included Botox in Medicare's drug price negotiation program, which allows Medicare officials to negotiate for lower drug prices, it overstepped its authority, drugmaker AbbVie Inc. told a D.C. federal court, arguing the cosmetic drug and migraine treatment is a "plasma-derived" product ineligible for price controls.

  • April 29, 2026

    Ropes & Gray Guides Italy's Chiesi On $1.9B US Biotech Deal

    Chiesi Group said Wednesday it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, expanding the Italian biopharmaceutical company's rare disease portfolio with a newly approved treatment for a rare hereditary swelling disorder. 

  • April 29, 2026

    Hogan Lovells Rehires Baker McKenzie Chair As Partner In DC

    Hogan Lovells has rehired an attorney who was most recently the chair of Baker McKenzie's U.S. healthcare and life sciences regulatory practice, who advises life sciences, food, consumer platform and technology companies.

  • April 28, 2026

    Allergan Seeks Sanctions Over Discovery In Botox Fight

    Botox manufacturer Allergan has asked a Tennessee federal judge to sanction Revance Therapeutics, claiming its attorneys made misrepresentations to run out the clock on discovery and prevent Allergan from obtaining essential information in a case alleging theft of trade secrets.

  • April 28, 2026

    5th Circ. Judge 'Hung Up' On FDA Vape Denial Reasoning

    A Fifth Circuit judge on Tuesday pressed the U.S. Food and Drug Administration on how it reviews applications from flavored vape manufacturers, asking why repeatedly denying applicants on similar grounds should not be treated as a rule requiring notice-and-comment.

  • April 28, 2026

    Teleflex Settles Catheter Patent Case Against Medtronic

    Medical device company Teleflex and Medtronic have reached a settlement to end a catheter patent dispute from which a judge recused himself after explaining he was "at a loss" on how to proceed.

  • April 28, 2026

    Ex-Fauci Adviser Charged With Concealing COVID Records

    Federal prosecutors have charged a former adviser to Dr. Anthony Fauci with deleting government emails and using his personal email account to dodge public records requests about the origins of the COVID-19 virus.

  • April 28, 2026

    Purdue Pharma's $5.5B Plea Deal Clinched As Survivors Protest

    OxyContin maker Purdue Pharma LP has to pay a $3.5 billion fine and forfeit an additional $2 billion, more than five years after it pled guilty to criminal charges related to its role in the opioid crisis, a New Jersey federal judge said Tuesday.

  • April 28, 2026

    MedMal Case Volume Declines, But Doctor Risks Remain High

    While the volume of malpractice lawsuits against U.S. physicians has dropped in recent years, that doesn't mean the threat of legal liability is dissipating, according to a report released Monday by the American Medical Association. 

  • April 28, 2026

    Paul Hastings, Gibson Dunn Steer $739M Ligand-Xoma Deal

    Ligand Pharmaceuticals said it plans to purchase XOMA Royalty in a $739 million deal combining the two biotechnology royalty aggregator companies advised by Gibson Dunn & Crutcher LLP and Paul Hastings LLP.

  • April 28, 2026

    Walgreens Can't Use Recording To Undo Investor Claim In Ill.

    An Illinois federal judge has said she won't toss a claim brought by shareholders alleging a former Walgreens president made a false and misleading statement during an investor conference, rejecting the company's argument that an audio recording of that conference warranted a second look at her dismissal ruling.

  • April 28, 2026

    Chinese Man Extradited From Italy Over COVID Data Theft

    A Chinese citizen has appeared before a Houston federal court after being extradited from Italy to face charges for his alleged role in the Microsoft "HAFNIUM" cyberattack that was allegedly orchestrated by the Chinese government to target U.S. COVID-19 research.

  • April 28, 2026

    Hikma, Cipla Cut Deals In Pfizer Heart Drug Patent Case

    Hikma Pharmaceuticals PLC and Cipla Ltd. have reached settlements with Pfizer Inc. in a case over the two defendants' efforts to create generic versions of the heart medication Vyndamax.

Expert Analysis

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here